Repurposing CD8(+) T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?

The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8(+) T cells for...

Descripción completa

Detalles Bibliográficos
Autores principales: Gujar, Shashi, Pol, Jonathan G., Kim, Youra, Kroemer, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Point-of-View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458627/
https://www.ncbi.nlm.nih.gov/pubmed/32923158
http://dx.doi.org/10.1080/2162402X.2020.1794424
_version_ 1783576237539590144
author Gujar, Shashi
Pol, Jonathan G.
Kim, Youra
Kroemer, Guido
author_facet Gujar, Shashi
Pol, Jonathan G.
Kim, Youra
Kroemer, Guido
author_sort Gujar, Shashi
collection PubMed
description The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8(+) T cells for cancer immunotherapy strategies.
format Online
Article
Text
id pubmed-7458627
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-74586272020-09-11 Repurposing CD8(+) T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic? Gujar, Shashi Pol, Jonathan G. Kim, Youra Kroemer, Guido Oncoimmunology Point-of-View The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8(+) T cells for cancer immunotherapy strategies. Taylor & Francis 2020-07-16 /pmc/articles/PMC7458627/ /pubmed/32923158 http://dx.doi.org/10.1080/2162402X.2020.1794424 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Point-of-View
Gujar, Shashi
Pol, Jonathan G.
Kim, Youra
Kroemer, Guido
Repurposing CD8(+) T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
title Repurposing CD8(+) T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
title_full Repurposing CD8(+) T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
title_fullStr Repurposing CD8(+) T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
title_full_unstemmed Repurposing CD8(+) T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
title_short Repurposing CD8(+) T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
title_sort repurposing cd8(+) t cell immunity against sars-cov-2 for cancer immunotherapy: a positive aspect of the covid-19 pandemic?
topic Point-of-View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458627/
https://www.ncbi.nlm.nih.gov/pubmed/32923158
http://dx.doi.org/10.1080/2162402X.2020.1794424
work_keys_str_mv AT gujarshashi repurposingcd8tcellimmunityagainstsarscov2forcancerimmunotherapyapositiveaspectofthecovid19pandemic
AT poljonathang repurposingcd8tcellimmunityagainstsarscov2forcancerimmunotherapyapositiveaspectofthecovid19pandemic
AT kimyoura repurposingcd8tcellimmunityagainstsarscov2forcancerimmunotherapyapositiveaspectofthecovid19pandemic
AT kroemerguido repurposingcd8tcellimmunityagainstsarscov2forcancerimmunotherapyapositiveaspectofthecovid19pandemic

Ejemplares similares